Crinetics Pharmaceuticals (CRNX) Non Operating Income (2017 - 2026)

Crinetics Pharmaceuticals' Non Operating Income history runs 10 years deep, the most recent figure standing at $12.5 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 14.34% year-over-year to $12.5 million; the TTM figure through Mar 2026 stood at $49.5 million (up 24.65% YoY), while the FY2025 annual figure was $51.6 million, up 26.19% from the prior year.
• Non Operating Income for Q1 2026 stood at $12.5 million, up from $11.0 million in the prior quarter.
• The five-year high for Non Operating Income was $14.6 million in Q1 2025, with the low at -$81000.0 in Q2 2022.
• The 5-year median for Non Operating Income is $6.8 million (2023), against an average of $6.6 million.
• The sharpest annual moves came in 2022 and 2025: Non Operating Income sank 179.31% in 2022, then jumped 103753.85% in 2025.
• Crinetics Pharmaceuticals' Non Operating Income stood at $92000.0 in 2022, then surged by 7250.0% to $6.8 million in 2023, then surged by 109.26% to $14.2 million in 2024, then declined by 22.04% to $11.0 million in 2025, then increased by 13.62% to $12.5 million in 2026.
• Business Quant data shows CRNX's Non Operating Income at $12.5 million in Q1 2026, $11.0 million in Q4 2025, and $12.5 million in Q3 2025.